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The coronavirus disease 2019 (COVID-19) pandemic is having an enormous impact on public health. Infection
with SARS-CoV-2 has become a leading cause of morbidity and mortality in many regions around the world. As
many COVID-19 patients are treated with antibiotics, there is concern regarding an associated rise in rates of
antimicrobial resistance (AMR). On the other hand, social distancing, isolation and reduced travel may result in
decreased spread of AMR. In this issue of JAC-Antimicrobial Resistance, we present a PRO/CON debate on the
question of the potential impact of COVID-19 on AMR rates.
In December 2019, a cluster of patients infected with a novel cor-
onavirus was recognized in Wuhan, China.1 This novel coronavirus
was found to be similar to the Severe Acute Respiratory Syndrome
(SARS)-coronavirus (CoV) and was named SARS-CoV-2. The associ-
ated disease was named coronavirus disease 2019 (COVID-19).
COVID-19 spread rapidly worldwide and at the time of writing over
6 000 000 cases have been confirmed, with over 300 000 deaths.2
The impact of the COVID-19 pandemic on antimicrobial resistance
(AMR) remains unclear.
Antibiotic use, often to treat presumed secondary bacterial
coinfection, is common in patients infected with SARS-CoV-2. This
is despite the relatively low rates of these infections. Furthermore,
early reports of the possible activity of hydroxychloroquine in
COVID-19 when used in combination with azithromycin led to sub-
stantial use of the latter.3 Another important feature of this dis-
ease is the prolonged dependence on invasive mechanical
ventilation of patients with severe infection. In a large cohort, 12%
of hospitalized patients in New York State required mechanical
ventilation.4 In a smaller Boston cohort of COVID-19 patients who
were managed with invasive mechanical ventilation, the median
duration was 16 days (IQR: 10.0–21.0 days).5 These prolonged in-
tensive care stays, high mortality rate, diagnostic and prognostic
uncertainty and concern for secondary bacterial infections has led
to frequent empiric antibacterial use. In Chinese randomized trials
evaluating remdesivir and lopinavir/ritonavir, over 90% of patients
were treated with antibacterials.6,7 In an analysis of published lit-
erature, Rawson et al.8 report that while only 8% of patients
included in publications had reported bacterial or fungal coinfec-
tion, 72% of patients were treated with antibiotics. This frequent
use of empiric antibiotics, often broad spectrum or in combination,
has led to concerns over increased AMR rates, with an attendant
call not to neglect antimicrobial stewardship, which perhaps now
has an even more important role.9
On the other hand, the COVID-19 pandemic has resulted in
unprecedented changes in society that may actually result in
decreased AMR rates. Social distancing, a focus on isolation and
reductions in national and international travel may decrease
the spread of AMR pathogens and associated AMR genes.
International travel has been consistently reported as an im-
portant risk factor for acquisition of AMR pathogens.10 In April
2020, the number of travellers going through US checkpoints
was reduced by 95% compared with 2019.11 In addition, social
distancing measures to limit the spread of SARS-CoV-2 has
impacted prevalence of other infectious diseases, most notably
influenza.12 These measures may similarly impact the spread
of AMR.
In this issue of JAC-Antimicrobial Resistance, we have invited
international thought leaders for a PRO/CON debate regarding the
impact of COVID-19 on AMR. Clancy and colleagues13 argue in fa-
vour of the premise that COVID-19 will result in an overall increase
in AMR rates. They argue that while overall hospital attendance
may have decreased, the patients who are admitted during the
pandemic have a higher likelihood of being treated with broad-
spectrum antibiotics, as well as being exposed to procedures, such
as invasive mechanical ventilation, that are known risk factors for
AMR development. In addition, many shared risk factors exist for
patients who are at risk of COVID-19 requiring hospitalization and
those at risk of AMR. Collignon and Beggs14 argue that COVID-19
will not lead to increased AMR rates. They present several import-
ant arguments, ranging from factors that impact transmission in
healthcare and community settings, to the impact of decreased
international travel. They also emphasize that control of AMR
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requires control of the spread of AMR pathogens, in addition to
antimicrobial stewardship.
The impact of COVID-19 on AMR rates remains to be deter-
mined and is likely to be heterogeneous due to variation in health-
care practices, such as in the specific antimicrobials used and
infection prevention and control interventions during the pandem-
ic. It is clearly an important area for future systematic studies.
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